BMS Bets $8.4bn On Biokin’s Bispecific ADC

New Validation Of Chinese Innovation

In a record licensing deal involving a single biopharma asset from China, Biokin and its US subsidiary SystImmune will receive up to $8.4bn from BMS, including $800m upfront, for a bispecific ADC with broad oncology potential.

acquisition deal — BL-B01D1 adds another ADC to BMS's diverse pipeline • Source: Shutterstock

Bristol Myers Squibb Company has gained access to the bispecific antibody-drug conjugate (ADC) BL-B01D1 from Shanghai-listed Sichuan Biokin Pharmaceutical, in a huge deal worth up to $8.4bn that the US major intends to ride to bolster its oncology pipeline across multiple possible indications.

The size of the alliance also adds further weight to the attractiveness of novel R&D in the ADC area coming...